AAV- microDystrophin and AAV-GDF5: A combined treatment to optimize DMD gene therapy ? - Sorbonne Université Access content directly
Conference Papers Year : 2022

AAV- microDystrophin and AAV-GDF5: A combined treatment to optimize DMD gene therapy ?

PRESENTATION EMBO 2022 finale.pdf (4.42 Mo) Télécharger le fichier

Dates and versions

hal-04000437 , version 1 (27-02-2023)

Identifiers

  • HAL Id : hal-04000437 , version 1

Cite

France Piétri‐rouxel. AAV- microDystrophin and AAV-GDF5: A combined treatment to optimize DMD gene therapy ?. EMBO 2022 Muscle formation, maintenance, regeneration and pathology, Fred Relaix, Apr 2022, Gouvieux, France. ⟨hal-04000437⟩
10 View
5 Download

Share

Gmail Mastodon Facebook X LinkedIn More